$19.46−0.68 (−3.38%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
NewAmsterdam Pharma (NAMS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 78% below its peak, net margin −905.7%. Worth your attention in FY25: Returns vs FCF (n/m). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼50.6%
22.5
FY21→FY25CAGR +585.6%/yr
Net income ($M)▲15.6%
−203.8
FY21→FY25CAGR —
Free cash flow ($M)▲7.0%
−148.0
FY21→FY25CAGR —
Diluted EPS▲32.8%
−1.72
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Capex
$246.0K
−63.4% YoY in FY25 · 1.1% of revenue.
Returns vs FCF
n/m
$1.6M returned vs $−148.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-906¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -905.7% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 25,937.0 | 22,503.0 | 45,563.0 | 14,090.0 | 102,694.0 | 10.2 | ▼50.6% | +585.6% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 25,937.0 | 22,503.0 | 45,563.0 | 14,090.0 | 102,694.0 | 10.2 | ▼50.6% | +585.6% |
Research & development | 157,633.0 | 141,832.0 | 151,406.0 | 159,424.0 | 86,744.0 | 28,331.2 | ▼6.3% | +49.6% |
Selling, general & admin | 101,755.0 | 106,354.0 | 70,446.0 | 37,633.0 | 19,507.0 | 5,436.0 | ▲51.0% | +110.3% |
Total operating expenses | 259,388.0 | 248,186.0 | 221,852.0 | 197,057.0 | 106,251.0 | 33,767.3 | ▲11.9% | +64.7% |
Operating incomefeeds ROC rank | −233,451.0 | −225,683.0 | −176,289.0 | −182,967.0 | −3,557.0 | −33,757.1 | ▼28.0% | — |
Other income, net | 29,770.0 | 21,864.0 | −65,310.0 | 6,057.0 | −19,077.0 | 1,388.7 | — | — |
Pretax income | −203,681.0 | −203,819.0 | −241,599.0 | −176,910.0 | −22,634.0 | −32,368.3 | ▲15.6% | — |
Income tax | 1,207.0 | 0.0 | −1.0 | 27.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −204,888.0 | −203,819.0 | −241,598.0 | −176,937.0 | −22,634.0 | −32,368.3 | ▲15.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.68 | −1.72 | −2.56 | −2.15 | −1.19 | −1.37 | ▲32.8% | — |
Diluted shares (mn) | 119.93 | 114.98 | 109.82 | 89.27 | 81.56 | — | ▲4.7% | +12.1% |
| Margins | ||||||||
Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −900.1% | −1002.9% | −386.9% | −1298.6% | −3.5% | −331406.5% | ▼616.0pp | +330403.6pp |
Net margin3rd pct in Healthcare | −789.9% | −905.7% | −530.3% | −1255.8% | −22.0% | −317772.9% | ▼375.5pp | +316867.2pp |
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-18 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was NewAmsterdam Pharma's revenue last fiscal year?
NewAmsterdam Pharma reported revenue of $22.5M in fiscal 2025, down 50.6% from fiscal 2024.
What was NewAmsterdam Pharma's net income?
NewAmsterdam Pharma reported net income of −$203.8M in fiscal 2025, a net margin of −905.7%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

